1887

Abstract

It has been shown that human group IIa secreted phospholipase A (sPLA), found at high levels in inflammatory fluids, displays direct bactericidal properties against Gram-positive bacteria, while activity against Gram-negative bacteria requires the complement system or additional co-factors produced by neutrophils. , an increasingly prevalent opportunistic human pathogen, is the most common Gram-negative rod found in cystic fibrosis lung infections, where it is associated with an inflammatory environment. Because murine intestinal group II sPLA produced by Paneth cells has been shown to be directly bactericidal against Gram-negative bacteria, IIa sPLA activity against clinical isolates was evaluated and provides the first evidence that the enzyme can be fully bactericidal in a concentration- and time-dependent manner against Gram-negative rods. Furthermore, it was demonstrated that these bactericidal properties were unaffected by high protein and salt concentrations, as observed in cystic fibrosis secretions, and that bacterial killing paralleled phospholipid hydrolysis. Finally, no cytotoxicity was observed when IIa sPLA was incubated with human pulmonary cells, highlighting its potential use to synergize bactericidal antibiotics by promoting sublethal alterations of the bacterial cell wall.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.05303-0
2003-12-01
2019-11-18
Loading full text...

Full text loading...

/deliver/fulltext/jmm/52/12/JM521202.html?itemId=/content/journal/jmm/10.1099/jmm.0.05303-0&mimeType=html&fmt=ahah

References

  1. Bligh, E. S. & Dyer, W. J. ( 1959;). A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37, 911–917.[CrossRef]
    [Google Scholar]
  2. Buckland, A. G., Heeley, E. L. & Wilton, D. C. ( 2000;). Bacterial cell membrane hydrolysis by secreted phospholipases A2: a major physiological role of human group IIa sPLA2 involving both bacterial cell wall penetration and interfacial catalysis. Biochim Biophys Acta 1484, 195–206.[CrossRef]
    [Google Scholar]
  3. Cystic Fibrosis Foundation ( 2001;). Patient Registry 2000 Annual Report. Bethesda, MD: Cystic Fibrosis Foundation.
  4. Davidsen, J., Jorgensen, K. Andersen, T. L. & Mouritsen, O. G. ( 2003;). Secreted phospholipase A2 as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue. Biochim Biophys Acta 1609, 95–101.[CrossRef]
    [Google Scholar]
  5. Doggett, R. G., Harrison, G. M., Stillwell, R. N. & Wallis, S. E. ( 1966;). An atypical Pseudomonas aeruginosa associated with cystic fibrosis of pancreas. J Pediatr 68, 215–221.[CrossRef]
    [Google Scholar]
  6. Doring, G., Conway, S. P., Heijerman, H. G., Hodson, M. E., Hoiby, N., Smyth, A. & Touw, D. J. ( 2000;). Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16, 749–767.[CrossRef]
    [Google Scholar]
  7. Elsbach, P., Weiss, J. & Levy, O. ( 1994;). Integration of antimicrobial host defenses: role of the bactericidal/permeability-increasing protein. Trends Microbiol 2, 324–328.[CrossRef]
    [Google Scholar]
  8. Fourcade, O., Simon, M. F., Viode, C., Rugani, N., Leballe, F., Ragab, A., Fournie, B., Sarda, L. & Chap, H. ( 1995;). Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell 80, 919–927.[CrossRef]
    [Google Scholar]
  9. Giwercman, B., Lambert, P. A., Rosdahl, V. T., Shand, G. H. & Hoiby, N. ( 1990;). Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed β-lactamase producing strains. J Antimicrob Chemother 26, 247–259.[CrossRef]
    [Google Scholar]
  10. Hancock, R. E. & Wong, P. G. ( 1984;). Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother 26, 48–52.[CrossRef]
    [Google Scholar]
  11. Harwig, S. S., Tan, L., Qu, X. D., Cho, Y., Eisenhauer, P. B. & Lehrer, R. I. ( 1995;). Bactericidal properties of murine intestinal phospholipase A2. J Clin Invest 95, 603–610.[CrossRef]
    [Google Scholar]
  12. Koduri, R. S., Grönroos, J. O., Laine, V. J. O., Le Calvez, C., Lambeau, G., Nevalainen, T. J. & Gelb, M. H. ( 2002;). Bactericidal properties of human and murine groups I, II, V, X, and XII secreted phospholipases A2. J Biol Chem 277, 5849–5857.[CrossRef]
    [Google Scholar]
  13. Laine, V. J. O., Grass, D. S. & Nevalainen, T. ( 1999;). Protection by group II phospholipase A2 against Staphylococcus aureus. J Immunol 162, 7402–7408.
    [Google Scholar]
  14. Laine, V. J. O., Grass, D. S. & Nevalainen, T. ( 2000;). Resistance of transgenic mice expressing human group II phospholipase A2 to Escherichia coli infection. Infect Immun 68, 87–92.[CrossRef]
    [Google Scholar]
  15. Lemnaouar, M., Chastre, E., Paul, A. & 8 other authors ( 1993;). Oncogene-mediated propagation of tracheal epithelial cells from two cystic fibrosis fetuses with different mutations.Characterization of CFT-1 and CFT-2 cells in culture. Eur J Clin Invest 23, 151–160.[CrossRef]
    [Google Scholar]
  16. Livermore, D. M. ( 1987;). Clinical significance of β-lactamase induction and stable derepression in gram-negative rods. Eur J Clin Microbiol 6, 439–445.[CrossRef]
    [Google Scholar]
  17. Murakami, M., Nakatani, Y., Atsumi, G., Inoue, K. & Kudo, I. ( 1997;). Regulatory functions of phospholipase A2. Crit Rev Immunol 17, 225–283.[CrossRef]
    [Google Scholar]
  18. Poole, K., Gotoh, N., Tsujimoto, H. & 7 other authors ( 1996a;). Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol 21, 713–724.[CrossRef]
    [Google Scholar]
  19. Poole, K., Tetro, K., Zhao, Q., Neshat, V., Heinrichs, D. E. & Bianco, N. ( 1996b;). Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression. Antimicrob Agents Chemother 40, 2021–2028.
    [Google Scholar]
  20. Qu, X.-D. & Lehrer, R. I. ( 1998;). Secretory phospholipase A2 is the principal bactericide for staphylococci and other Gram-positive bacteria in human tears. Infect Immun 66, 2791–2797.
    [Google Scholar]
  21. Richmond, M. H. & Sykes, R. B. ( 1973;). The β-lactamases of gram-negative bacteria and their possible physiological role. Adv Microb Physiol 9, 31–88.
    [Google Scholar]
  22. Smith, J. J., Travis, S. M., Greenberg, E. P. & Welsh, M. J. ( 1996;). Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85, 229–236.[CrossRef]
    [Google Scholar]
  23. Valdas, P., Browning, J., Edelson, J. & Pruzanski, W. ( 1993;). Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J Lipid Mediat 8, 1–30.
    [Google Scholar]
  24. Weinrauch, Y., Foreman, A., Shu, C., Zarember, K., Levy, O., Elsbach, P. & Weiss, J. ( 1995;). Extracellular accumulation of potently microbicidal bactericidal/permeability-increasing protein and p15s in a evolving sterile rabbit peritoneal inflammatory exudate. J Clin Invest 95, 1916–1924.[CrossRef]
    [Google Scholar]
  25. Weinrauch, Y., Elsbach, P., Madsen, L. M., Foreman, A. & Weiss, J. ( 1996;). The potent anti-Staphylococcus aureus activity of a sterile rabbit inflammatory fluid is due to a 14-kD phospholipase A2. J Clin Invest 97, 250–257.[CrossRef]
    [Google Scholar]
  26. Weinrauch, Y., Abad, C., Liang, N.-S., Lowry, S. F. & Weiss, J. ( 1998;). Mobilization of potent plasma bactericidal activity during systemic bacterial challenge.Role of group IIA phospholipase A2. J Clin Invest 102, 633–638.[CrossRef]
    [Google Scholar]
  27. Yoshimura, F. & Nikaido, H. ( 1982;). Permeability of Pseudomonas aeruginosa outer membrane to hydrophilic solutes. J Bacteriol 152, 636–642.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.05303-0
Loading
/content/journal/jmm/10.1099/jmm.0.05303-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error